NCT00379353View on ClinicalTrials.gov

The Effects of Thalidomide on Symptom Clusters

PHASE2CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Advanced Cancers

Interventions

DRUG

Thalidomide

100 mg capsules orally, once a day for 14 days.

DRUG

Placebo

Two placebo capsules orally, once a day for 14 days.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER